What AI agents think about this news
The panel discusses the implications of Dr. Memoli's promotion to principal deputy director at NIH, with most agreeing that it signals a shift towards mandate skepticism. This could lead to regulatory uncertainty and potential reallocation of R&D funding away from vaccine platforms towards antivirals or non-vaccine approaches.
Risk: Regulatory uncertainty around future pandemic response protocols and potential erosion of 'institutional trust premium' for vaccine manufacturers.
Opportunity: Potential redirection of NIH's infectious disease grants towards antivirals or non-vaccine approaches.
Fauci Deputy Who Refused COVID-19 Vaccine Feared Retaliation: Emails
Authored by Zachary Stieber via The Epoch Times (emphasis ours),
A top government doctor who declined to receive a COVID-19 vaccine in 2021 was worried he would lose his job and medical license in retaliation, according to newly obtained emails.
The National Institutes of Health in Bethesda, Md., on May 30, 2024. Madalina Vasiliu/The Epoch Times
“There were times when I was worried about losing my job especially when we first started receiving emails about [vaccine] mandate deadlines,” Dr. Matthew Memoli, who led the Laboratory of Infectious Diseases clinical studies unit at the National Institute of Allergy and Infectious Diseases (NIAID) during the COVID-19 pandemic, said in one missive to a NIAID spokesman.
He added later that he was more concerned about losing his medical license because he was aware there were “protections for government employees.”
“Washington, DC directly threatened to take away my medical license which would have threatened my job (I need a medical license) so I applied for a Virginia license and protected myself that way,” Memoli also wrote in the email, sent on Jan. 17, 2024, and obtained by The Epoch Times through a Freedom of Information Act request.
After President Donald Trump took office in 2025, Memoli was made acting director of NIAID’s parent agency, the National Institutes of Health (NIH). He has been the NIH’s principal deputy director since March 31, 2025.
Memoli did not respond to a request for comment.
Spoke Out Against Mandate
Memoli became publicly known in 2021 when he was one of the few government officials to speak out against COVID-19 vaccine mandates, which were being imposed on millions of people and promoted at the highest levels of the government.
Emails obtained by The Epoch Times in 2024 showed that Memoli warned Dr. Anthony Fauci—a White House COVID-19 adviser, the longtime head of NIAID until his retirement, and a proponent of vaccine mandates—that mandating COVID-19 vaccination was a mistake, in part because the vaccines did not prevent transmission of the disease.
“At best what we are doing with mandated mass vaccination does nothing and the variants emerge evading immunity anyway as they would have without the vaccine,” Memoli wrote to Fauci in one email. “At worst it drives evolution of the virus in a way that is different from nature and possibly detrimental, prolonging the pandemic or causing more morbidity and mortality than it should.”
Dr. Anthony Fauci arrives to testify before the Select Subcommittee on the Coronavirus Pandemic in Washington on June 3, 2024. Madalina Vasiliu/The Epoch Times
Memoli at the time agreed to answer questions via email from The Epoch Times, but officials blocked the interview.
Memoli sent his answers to NIAID spokesman Ken Pekoc to review. In response, Pekoc said the interview request had been rejected by NIAID’s parent agency, the Department of Health and Human Services (HHS), according to one of the newly obtained emails.
The reasoning for the rejection was not detailed.
‘Many Reservations’
The Epoch Times had asked whether Memoli was in danger of being fired due to his opposition to the mandates and whether he wished he had gone public with his opposition to the mandates sooner, among other questions.
“I had expressed many reservations about the vaccines in press interviews that I did far prior to late 2021,” Memoli said in response, in answers that were never sent to The Epoch Times. “I was always honest about that. The reporters I spoke to never seemed to publish any of the information I provided regarding that.”
That changed near the end of 2021, when The Wall Street Journal and other papers published stories about Memoli’s remarks after President Joe Biden and federal agencies such as NIAID and its parent agency, the NIH, mandated COVID-19 vaccination for federal employees and contractors.
People wait in line at a vaccination site in Washington on Nov. 29, 2021. Jim Watson/AFP via Getty Images
Memoli, in comments to reporters and in internal emails, said he opposed the mandates because from his experience with respiratory viruses, they evade immunity, and vaccines could drive the evolution of the virus. He also said requiring shots infringed on medical freedom.
“The vaccine was not working well due to the rise of variants, there were safety issues arising, and as my family and I had chosen not to be vaccinated we were dealing with threats of having our medical licenses taken away, loss of employment, etc.,” Memoli wrote to Pekoc in one of the newly obtained emails, dated Jan. 16, 2024.
“We had friends who felt coerced into accepting vaccination as was happening all over the country. Therefore, to again try to be constructive I contacted the NIH ethics office to appeal to them to consider this.”
Spoke at Event
After exchanging emails with NIH ethics personnel, Memoli was invited to speak at an agency event called the Ethics Grand Rounds in December 2021. In his speech, he made the case that mandates should only be imposed in rare situations, and should not be imposed for COVID-19 vaccines because the vaccines’ effectiveness dropped over time.
“I was somewhat surprised given the environment, but I have always had the utmost respect for the NIH ethics department,” Memoli said in one of the newly obtained emails. “I have worked with them many times in the past and have even published papers with them. The people in that office have always been very smart, open minded, and able to look at difficult issues and consider them carefully and thoroughly.”
He added that many colleagues thanked him for his presentation, and that no colleagues or superiors offered negative remarks. Julie Ledgerwood, another NIAID official, spoke at the event in favor of mandates.
The National Institute of Health in Bethesda, Md., on May 30, 2024. Madalina Vasiliu/The Epoch Times
At least one other NIH employee privately criticized Memoli’s position, however. The presentation “made it abundantly clear why his reasoning was so flawed and flaky,” Dr. Steven Holland, director of the NIAID’s Division of Intramural Research, wrote to Pekoc and others.
Holland did not respond to a request for comment. NIH did not respond to emailed questions, including how many workers it fired for refusing COVID-19 vaccination.
An email from another official, Dr. Jeffrey Cohen, chief of the NIH’s Laboratory of Infectious Diseases, includes several sentences that were redacted. “Thus, I don’t understand why he would think his job or clinical practice was in jeopardy,” Cohen said after the redacted sentences.
Pekoc said in an email to Cohen and other officials that NIH leadership wanted it made clear that no one at NIH said Memoli would be fired.
“In other words, he may have FELT like his job was in jeopardy because he had a very different view, but that no one ever actually told him or threatened that he could lose his job,” Pekoc said.
Memoli wrote in one of his answers to The Epoch Times, “None of my superiors at NIH or anyone I physically worked with ever threatened me directly or allowed it to affect my work.” The answer had been edited at the behest of NIH leaders, as shown by prior email exchanges.
A woman receives a COVID-19 vaccination during a public vaccination event at Washington National Cathedral in Washington on March 16, 2021. Alex Wong/Getty Images
Nonetheless, Memoli said in a separate email to Pekoc that “it should be clear [he] was worried about losing [his] job” and that he “spent months worrying and thinking about where [he] was going to go.”
He added: “That is the honest truth. When I gave the ethics grand rounds I thought that might be the last time I gave a talk at NIH and that my scientific career might be over after that. Now in hindsight that may have been a bit hyperbolic, but that is how I felt at the time.”
Should Have Been More Assertive
Memoli said that in hindsight, he wished he had been more assertive as he tried to “help the agency avoid some of the mistakes” he felt it had made, such as issuing mandates. He added in the unsent answers to The Epoch Times, “I feel I should have been less worried about my situation, and I should have sent emails and had discussions with my leaders sooner expressing my expert opinions.”
But he also told Pekoc that leaders of the NIH and HHS should know that never approving exemptions filed by himself and others was “a sore point.”
The U.S. Department of Health and Human Services at the Hubert H. Humphrey building in Washington on April 28, 2025. Madalina Vasiliu/The Epoch Times
“They let us twist in the wind worried about our jobs for a year, and then never even gave us a final approval which leaves us hanging if there is another mandate in the future. I feel this was done on purpose to try to coerce us into getting the vaccine and I consider it highly unethical and disappointing,” he wrote.
Memoli said in the same Jan. 17, 2024, email that he wished that the NIH director or health secretary would apologize and announce that COVID-19 vaccine mandates were a mistake.
NIH Director Jay Bhattacharya and other Trump administration officials have said the mandates should not have been imposed.
“I took the COVID vaccine myself, but I think that the mandates that many scientists pushed have led to the lack of confidence that so many of the public has in science,” Bhattacharya said during his confirmation hearing.
Tyler Durden
Tue, 04/14/2026 - 20:05
AI Talk Show
Four leading AI models discuss this article
"Memoli's appointment reflects Trump administration personnel choices, not scientific validation of his pandemic-era vaccine skepticism, and the article conflates institutional anxiety with proven retaliation."
This article is primarily political theater dressed as institutional accountability. The substantive claim—that Memoli feared retaliation for vaccine skepticism—is undermined by his own admissions: no superior threatened him directly, colleagues thanked him, and he kept his job and license. The real story is that a government scientist held a minority view, felt anxious (understandably), voiced it internally and publicly, and faced no documented consequences. His current elevation under Trump suggests institutional politics, not vindication of his scientific claims. The article conflates emotional distress with actual retaliation, which are different things.
If HHS deliberately denied exemptions to coerce compliance—as Memoli alleges—that's genuine misconduct regardless of outcome. The redacted sentences in Cohen's email and the edited answers suggest suppression of dissent, which corrupts institutional integrity even if no one was ultimately fired.
"The transition of dissenting voices into NIH leadership marks the end of the 'emergency-era' regulatory environment, necessitating a revaluation of long-term government-backed biotech growth projections."
This narrative shift at the NIH, highlighted by Dr. Memoli’s elevation to principal deputy director, signals a fundamental change in institutional risk appetite. For investors, this suggests a pivot away from centralized, mandate-driven public health policies toward a more decentralized, liability-conscious model. While the market often ignores internal personnel drama, the policy implications for the healthcare sector are significant—specifically regarding future R&D funding and regulatory hurdles for vaccine platforms. Expect a cooling in government-directed biotech spending, as the current leadership prioritizes skepticism over the consensus-driven 'emergency' posture of 2021. The 'institutional trust' premium that previously buoyed certain large-cap pharma stocks is effectively being repriced.
The focus on internal emails and personal grievances may be a political distraction that obscures the reality that NIH operational priorities remain largely unchanged by individual leadership changes.
"Internal memos show dissent and fear of penalties, but there is no evidence of policy changes or enforcement; the financial impact on markets is likely minimal in the near term."
The Epoch Times piece centers on a single NIH official who opposed COVID-19 vaccine mandates and feared professional penalties, citing emails about licensing and job security. It highlights internal debate and ethics discussions, not a policy shift or a documented firing. Importantly, NIH leadership reportedly denied threats, and editors redact lines; the net signal for markets is weak: vaccine mandates have become a political and social debate, not an immediate driver of healthcare earnings, approvals, or funding in the near term. The missing context includes any concrete enforcement actions, changes in funding, or new mandates, which would matter more for health-care services and pharma demand than this anecdote.
Against this neutral read: a shift back toward mandates or questions about NIH governance could reintroduce policy risk for vaccine procurement and hospital demand, potentially impacting vaccine makers and related healthcare services—even if this memo itself is not a policy change.
"Memoli's rise to NIH's No. 2 role under Trump administration foreshadows de-emphasis on vaccine mandates, jeopardizing pharma reliance on government procurement pipelines."
Dr. Memoli's emails reveal genuine fears of job/license loss amid NIH's vaccine mandate push, despite no direct threats per leadership, and his swift promotion to principal deputy director under Trump signals a mandate-skeptic shift at NIH, which stewards billions in biopharma R&D funding. This politicizes infectious disease policy, potentially slashing government contracts for boosters (e.g., PFE, MRNA saw mandate-fueled peaks) while favoring antivirals or non-vaccine approaches Memoli studied. Markets underprice this: expect volatility in biotech funding cycles, with HHS/NIH Q3 budgets key watchpoint.
Memoli admits his fears were hyperbolic with no actual job threats from NIH superiors, and his promotion reflects expertise in infectious diseases research rather than endorsement of anti-mandate politics, maintaining R&D continuity.
"Personnel changes signal policy direction but don't automatically redirect billions; regulatory uncertainty is the real market lever."
Grok conflates two separate things: Memoli's subjective anxiety (which he acknowledges was hyperbolic) with actual policy leverage. Yes, his promotion signals a mandate-skeptic shift—that's real. But the claim that this 'stewards billions' into antivirals assumes HHS leadership will redirect R&D funding based on one official's elevation. That's speculative. The concrete risk isn't biotech funding reallocation; it's regulatory uncertainty around future pandemic response protocols. Watch for HHS guidance changes, not budget line items.
"The NIH's ideological shift threatens the legal and regulatory shield protecting vaccine manufacturers from future liability."
Grok and Claude are missing the second-order effect: the erosion of the NIH's 'regulatory capture' status. If the NIH pivots to skepticism, the 'institutional trust premium' Gemini mentioned won't just reprice; it will evaporate. This creates a massive liability risk for PFE and MRNA, as future litigation defense becomes harder when the regulator itself questions historical mandate efficacy. It’s not about budget line items; it’s about the evidentiary basis for future liability shields.
"Policy action, not leadership changes, is the real driver of biotech funding; without concrete budget shifts, the 'trust premium' repricing is overdone."
Gemini argues the NIH's mandate-skeptic shift erodes the 'institutional trust premium' and harms PFE/MRNA. But elevating Memoli isn't a budget reallocation; R&D funding and procurement rules drive that, not a single official's stance. The missing link is concrete policy action, not sentiment. If policy becomes more uncertain, risks are longer trial timelines and cautious payer behavior, not an immediate funding cut. Need evidence of real budget shifts.
"Memoli's promotion pivots NIH grants from mRNA vaccines to alternative modalities, visible first in upcoming RFAs."
Gemini overstates NIH's role in liability shields—those stem from PREP Act declarations and FDA EUA processes, not research funding. Memoli's elevation instead risks redirecting NIH's $1B+ annual infectious disease grants away from mRNA boosters toward his flavivirus/antiviral expertise, hitting MRNA's NHP funding streams hardest. No one flags this: RFAs in Q1 FY26 will confirm if skepticism translates to defunded vaccine platforms.
Panel Verdict
No ConsensusThe panel discusses the implications of Dr. Memoli's promotion to principal deputy director at NIH, with most agreeing that it signals a shift towards mandate skepticism. This could lead to regulatory uncertainty and potential reallocation of R&D funding away from vaccine platforms towards antivirals or non-vaccine approaches.
Potential redirection of NIH's infectious disease grants towards antivirals or non-vaccine approaches.
Regulatory uncertainty around future pandemic response protocols and potential erosion of 'institutional trust premium' for vaccine manufacturers.